https://en.bioecon.ru/technologies/allogeneic-cell-therapy/Recent content in Allogeneic-Cell-Therapy on BioeconHugoen-USMon, 20 Jul 2026 13:01:09 +0700https://en.bioecon.ru/technology/car-t-cell-therapy/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/car-t-cell-therapy/A patient’s own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast’s Ryoncil for steroid-refractory GVHD and TiGenix’s Alofisel for Crohn’s fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.